Clinical Trial Update: The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria [Phase 4]

View source ↗

Summary

This clinical trial update reports on changes in urinary angiotensinogen excretion after valsartan treatment in patients with persistent proteinuria (Phase 4).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Proteinuria

Drugs mentioned

• VALSARTAN (Valsartan)

Snippet

Sponsor: Samsung Medical Center | Conditions: Chronic Kidney Disease, Proteinuria | Phase 4 | Status: UNKNOWN